Key result
MR-guided adaptive radiation yields 6-month disease stability in recurrent cardiac intimal sarcoma.
Why the study?
There are no prior reports of treating recurrent intimal sarcoma of the heart with stereotactic MR-guided online adaptive radiation therapy.
Is stereotactic MR-guided online adaptive radiation therapy feasible and effective for recurrent intimal sarcoma of the heart?
Is stereotactic MR-guided online adaptive radiation therapy feasible and effective for recurrent intimal sarcoma of the heart?
Stereotactic MR-guided online adaptive radiation therapy may be a feasible and well-tolerated treatment option for recurrent cardiac intimal sarcoma.
May support MR-guided adaptive RT in rare recurrent cardiac sarcoma; leaves open prospective confirmation of efficacy and safety.
We present the first case in the literature of a patient with a histology-proven intimal sarcoma of the heart, recurrent after surgery, treated with stereotactic MR-guided online adaptive radiation therapy on an MR-Linac machine. The treatment was feasible and well tolerated. The CT scan 6 months after the last treatment showed stable disease.
No takes yet. Share an insight, caveat, or question.
Pomp et al. (2021) studied this question. Stereotactic MR-guided online adaptive radiation therapy was feasible, well tolerated, and resulted in stable disease at 6 months in a patient with recurrent intimal sarcoma of the heart.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: